Theriva Biologics, Inc. (TOVX)
0.243
+0.01
(+3.36%)
USD |
NYAM |
Aug 25, 11:40
Theriva Biologics Enterprise Value : 3.005M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 3.005M |
| August 21, 2026 | 3.001M |
| August 20, 2026 | 2.780M |
| August 19, 2026 | 2.560M |
| August 18, 2026 | 2.565M |
| August 17, 2026 | 3.120M |
| August 14, 2026 | 2.680M |
| August 13, 2026 | 2.771M |
| August 12, 2026 | 3.230M |
| August 11, 2026 | 2.771M |
| August 10, 2026 | 2.817M |
| August 07, 2026 | 2.349M |
| August 06, 2026 | 2.533M |
| August 05, 2026 | 2.546M |
| August 04, 2026 | 2.698M |
| August 03, 2026 | 2.436M |
| July 31, 2026 | 1.854M |
| July 30, 2026 | 1.858M |
| July 29, 2026 | 2.266M |
| July 28, 2026 | 2.012M |
| July 27, 2026 | 1.991M |
| July 24, 2026 | 2.446M |
| July 23, 2026 | 2.175M |
| July 22, 2026 | 2.684M |
| July 21, 2026 | 2.771M |
| Date | Value |
|---|---|
| July 20, 2026 | 2.725M |
| July 17, 2026 | 3.276M |
| July 16, 2026 | 2.698M |
| July 15, 2026 | 3.363M |
| July 14, 2026 | 3.235M |
| July 13, 2026 | 2.955M |
| July 10, 2026 | 3.317M |
| July 09, 2026 | 2.978M |
| July 08, 2026 | 3.129M |
| July 07, 2026 | 3.019M |
| July 06, 2026 | 3.841M |
| July 02, 2026 | 3.735M |
| July 01, 2026 | 3.717M |
| June 30, 2026 | 3.698M |
| June 29, 2026 | 1.194M |
| June 26, 2026 | 0.726M |
| June 25, 2026 | 0.2304M |
| June 24, 2026 | 0.2304M |
| June 23, 2026 | 0.8729M |
| June 22, 2026 | 0.8683M |
| June 18, 2026 | 0.7857M |
| June 17, 2026 | 1.653M |
| June 16, 2026 | 2.002M |
| June 15, 2026 | 2.754M |
| June 12, 2026 | 3.204M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ironwood Pharmaceuticals, Inc. | 1.000B |
| Nkarta, Inc. | 76.28M |
| Unicycive Therapeutics, Inc. | 88.06M |
| OnKure Therapeutics, Inc. | -17.93M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.217M |
| Total Expenses (Quarterly) | 3.217M |
| EPS Diluted (Quarterly) | -0.0701 |
| Earnings Yield | -275.2% |
| Normalized Earnings Yield | -281.28 |